tiprankstipranks
Advertisement
Advertisement

ARCT Stock Latest News

Arcturus Therapeutics: Buy Rating Backed by Advancing mRNA Programs and De-Risked CF Manufacturing Partnership
RatingsArcturus Therapeutics: Buy Rating Backed by Advancing mRNA Programs and De-Risked CF Manufacturing Partnership
15d ago
ARCT
Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
PremiumThe Fly
Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
19d ago
TMO
ARCT
Arcturus Therapeutics Announces Thermo Fisher mRNA Partnership
PremiumCompany Announcements
Arcturus Therapeutics Announces Thermo Fisher mRNA Partnership
19d ago
8K
ARCT
Arcturus announces collaboration with Thermo Fisher to advance ARCT-032
PremiumThe Fly
Arcturus announces collaboration with Thermo Fisher to advance ARCT-032
19d ago
TMO
ARCT
Arcturus Therapeutics initiated with a Buy at Freedom Broker
PremiumThe Fly
Arcturus Therapeutics initiated with a Buy at Freedom Broker
19d ago
ARCT
Arcturus Shareholders Back Board, Pay, and Auditor
PremiumCompany AnnouncementsArcturus Shareholders Back Board, Pay, and Auditor
2M ago
8K
ARCT
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
Premium
Company Announcements
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
2M ago
ARCT
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
Premium
Ratings
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
2M ago
ARCT
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
PremiumRatings
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
2M ago
ARCT
Arcturus Therapeutics Signals Progress Amid Revenue Slip
PremiumCompany Announcements
Arcturus Therapeutics Signals Progress Amid Revenue Slip
2M ago
ARCT
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
PremiumRatings
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
2M ago
ARCT
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
PremiumCompany Announcements
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
2M ago
8K
ARCT
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
PremiumThe FlyArcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
2M ago
ARCT
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
ARCT
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
Premium
Market News
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
3M ago
WGS
ARCT
Arcturus Therapeutics initiated with a Buy at B. Riley
PremiumThe Fly
Arcturus Therapeutics initiated with a Buy at B. Riley
4M ago
ARCT
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
PremiumThe Fly
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
5M ago
ARCT
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
PremiumCompany Announcements
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
5M ago
ARCT
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
PremiumCompany Announcements
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
5M ago
ARCT
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
PremiumThe FlyArcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
5M ago
ARCT
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
Premium
Ratings
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
5M ago
ARCT
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
Premium
Ratings
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
5M ago
ARCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >